1. Home
  2. VRDN vs CET Comparison

VRDN vs CET Comparison

Compare VRDN & CET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • VRDN
  • CET
  • Stock Information
  • Founded
  • VRDN 2006
  • CET 1929
  • Country
  • VRDN United States
  • CET United States
  • Employees
  • VRDN N/A
  • CET N/A
  • Industry
  • VRDN Medical Specialities
  • CET Finance/Investors Services
  • Sector
  • VRDN Health Care
  • CET Finance
  • Exchange
  • VRDN Nasdaq
  • CET Nasdaq
  • Market Cap
  • VRDN 1.6B
  • CET 1.5B
  • IPO Year
  • VRDN N/A
  • CET N/A
  • Fundamental
  • Price
  • VRDN $20.78
  • CET $51.39
  • Analyst Decision
  • VRDN Strong Buy
  • CET
  • Analyst Count
  • VRDN 10
  • CET 0
  • Target Price
  • VRDN $36.33
  • CET N/A
  • AVG Volume (30 Days)
  • VRDN 718.1K
  • CET 31.1K
  • Earning Date
  • VRDN 11-11-2025
  • CET 01-01-0001
  • Dividend Yield
  • VRDN N/A
  • CET 4.48%
  • EPS Growth
  • VRDN N/A
  • CET N/A
  • EPS
  • VRDN N/A
  • CET 7.40
  • Revenue
  • VRDN $305,000.00
  • CET $27,062,484.00
  • Revenue This Year
  • VRDN N/A
  • CET N/A
  • Revenue Next Year
  • VRDN $34,044.63
  • CET N/A
  • P/E Ratio
  • VRDN N/A
  • CET $6.91
  • Revenue Growth
  • VRDN 5.90
  • CET 15.78
  • 52 Week Low
  • VRDN $9.90
  • CET $40.24
  • 52 Week High
  • VRDN $27.20
  • CET $52.42
  • Technical
  • Relative Strength Index (RSI)
  • VRDN 54.30
  • CET 55.05
  • Support Level
  • VRDN $20.69
  • CET $50.63
  • Resistance Level
  • VRDN $22.37
  • CET $52.42
  • Average True Range (ATR)
  • VRDN 0.97
  • CET 0.84
  • MACD
  • VRDN -0.06
  • CET -0.12
  • Stochastic Oscillator
  • VRDN 54.71
  • CET 44.75

About VRDN Viridian Therapeutics Inc.

Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate includes Veligrotug (formerly known as VRDN-001) for intravenous (IV) and VRDN-003 for subcutaneous (SC) administration. Veligrotug is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of thyroid eye disease (TED).

About CET Central Securities Corporation

Central Securities Corp is a non-diversified closed-end management investment company. Its investment objective is long-term growth of capital. The company invests in common stocks, bonds, convertible bonds, preferred stocks, convertible preferred stocks, warrants, options real estate, or short-term obligations of governments, banks, and corporations.

Share on Social Networks: